Company Profile

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. Connect with us on XLinkedIn and Facebook.

Industry Classifications

Sector

Biopharmaceutical

Industry

Biotechnology

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

Contact Information

Investor Relations

Corbus Pharmaceuticals
Sean Moran
Chief Financial Officer
ir@corbuspharma.com

LifeSci Advisors, LLC
Bruce Mackle
Managing Director
T: 617.415.7745
bmackle@lifesciadvisors.com

Transfer Agent

Continental Stock Transfer & Trust Company
17 Battery Place
New York, NY 10004
T: 800.509.5586
cstmail@continentalstock.com
https://www.continentalstock.com

Company Contact

Corbus Pharmaceuticals Holdings, Inc.
500 River Ridge Drive
Norwood, MA 02062
T: 617.963.0100
F: 617.663.6085
info@corbuspharma.com